2ರಿಂದ 18 ವರ್ಷದ ಮಕ್ಕಳಿಗೆ ಭಾರತ್ ಬಯೋಟೆಕ್ನ ಕೊವ್ಯಾಕ್ಸಿನ್ ಲಸಿಕೆ ನೀಡಲು ವಿಷಯ ತಜ್ಞರ ಸಮಿತಿ ಸಭೆಯಲ್ಲಿ ಅನುಮತಿ ಸಿಕ್ಕಿದೆ.
the SEC has given a recommendation to Drugs Controller General of India (DGCI) for the use of Bharat Biotech's Covaxin for 2-18-year-olds, news agency ANI reported on Tuesday, 12 October, quoting official sources
the SEC has given a recommendation to Drugs Controller General of India (DGCI) for the use of Bharat Biotech's Covaxin for 2-18-year-olds, news agency ANI reported on Tuesday, 12 October, quoting official sources
Category
🗞
News